Craig A. Erickson mainly investigates Autism, Psychiatry, Developmental disorder, Fragile X syndrome and Irritability. His study in Autism focuses on Autism spectrum disorder in particular. His Psychiatry research is multidisciplinary, incorporating perspectives in Tolerability and Adverse effect.
The various areas that he examines in his Developmental disorder study include Olanzapine and Clinical psychology. His Clinical psychology research is multidisciplinary, relying on both Developmental psychology, Treatment modality, Constipation and Diet therapy. His work carried out in the field of Fragile X syndrome brings together such families of science as Neurology and Neuroscience.
The scientist’s investigation covers issues in Autism, Psychiatry, Autism spectrum disorder, Fragile X syndrome and Clinical psychology. His Autism research is multidisciplinary, incorporating elements of Young adult, Tolerability, Adverse effect, Placebo and Pediatrics. His Adverse effect research focuses on Severity of illness and how it connects with Pervasive developmental disorder and Developmental disorder.
His work on Aripiprazole, Risperidone and Aggression as part of general Psychiatry study is frequently linked to Irritability and Acamprosate, bridging the gap between disciplines. Craig A. Erickson combines subjects such as Clinical trial, Cognition, Neuroscience, Electroencephalography and Intellectual disability with his study of Fragile X syndrome. His research integrates issues of Cognitive behavioral therapy, Anxiety, Social skills, Public health and Treatment modality in his study of Clinical psychology.
His main research concerns Fragile X syndrome, Autism spectrum disorder, Clinical psychology, Autism and Cognition. His Fragile X syndrome study integrates concerns from other disciplines, such as Anxiety, Pharmacology, Intellectual disability and Electroencephalography. The concepts of his Autism spectrum disorder study are interwoven with issues in Pupillometry and Typically developing.
His Clinical psychology research incorporates themes from Eye tracking, Reactivity and Pupil, Pupillary response. Craig A. Erickson combines subjects such as Clinical trial, Allergy, Pediatrics, Infant formula and Comorbidity with his study of Autism. The various areas that Craig A. Erickson examines in his Pediatrics study include Ketamine, Adverse effect, Intranasal Ketamine, Young adult and Placebo.
His primary scientific interests are in Autism spectrum disorder, Intellectual disability, Clinical psychology, Temporal cortex and Fragile X syndrome. Autism spectrum disorder combines with fields such as Mechanism and Irritability in his research. Irritability overlaps with fields such as Aripiprazole, Psychiatry, Mood Lability, Anxiety and Aggression in his research.
His research combines Risperidone and Aripiprazole. His Temporal cortex research incorporates elements of Event-related potential, Electroencephalography, Audiology, Efference copy and Speech production. His Language delay research is multidisciplinary, relying on both Causes of autism, Developmental regression, Autism and Cohort.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Gastrointestinal Symptoms in a Sample of Children with Pervasive Developmental Disorders
Roumen N. Nikolov;Karen E. Bearss;Jelle Lettinga;Craig Erickson.
Journal of Autism and Developmental Disorders (2009)
Gastrointestinal factors in autistic disorder: a critical review.
Craig A. Erickson;Craig A. Erickson;Kimberly A. Stigler;Kimberly A. Stigler;Mark R. Corkins;Mark R. Corkins;David J. Posey;David J. Posey.
Journal of Autism and Developmental Disorders (2005)
Antipsychotics in the treatment of autism
David J. Posey;Kimberly A. Stigler;Craig A. Erickson;Christopher J. McDougle.
Journal of Clinical Investigation (2008)
SPARK: A US Cohort of 50,000 Families to Accelerate Autism Research
Pamela Feliciano;Amy M. Daniels;LeeAnne Green Snyder;Amy Beaumont.
Aggression in autism spectrum disorder: presentation and treatment options
Sarah E Fitzpatrick;Laura Srivorakiat;Logan K Wink;Ernest V Pedapati.
Neuropsychiatric Disease and Treatment (2016)
A retrospective study of memantine in children and adolescents with pervasive developmental disorders
Craig A. Erickson;Craig A. Erickson;David J. Posey;David J. Posey;Kimberly A. Stigler;Kimberly A. Stigler;Jennifer Mullett;Jennifer Mullett.
Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders.
Christopher J McDougle;Kimberly A Stigler;Craig A Erickson;David J Posey.
The Journal of Clinical Psychiatry (2008)
STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study
Craig A. Erickson;Jeremy M. Veenstra-Vanderweele;Raun D. Melmed;James T. McCracken.
Journal of Autism and Developmental Disorders (2014)
Diagnosing Autism Spectrum Disorder from Brain Resting-State Functional Connectivity Patterns Using a Deep Neural Network with a Novel Feature Selection Method
Xinyu Guo;Xinyu Guo;Kelli C. Dominick;Ali A. Minai;Hailong Li.
Frontiers in Neuroscience (2017)
Updated report on tools to measure outcomes of clinical trials in fragile X syndrome.
Dejan B. Budimirovic;Elizabeth Berry-Kravis;Craig A. Erickson;Scott S. Hall.
Journal of Neurodevelopmental Disorders (2017)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: